Earnings (loss) per share

12 Months Ended

Dec. 31, 2024

NOTE 18—Earnings (loss) per share:

The net income (loss) attributable to Teva and the weighted average number of ordinary shares used in the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2024, 2023 and 2022 are as follows:


	Year ended December, 31
	2024			2023			2022
	(U.S. $ in millions, except share data)
Net income (loss) used for the computation of basic and diluted earnings (loss) per share	$	(1,639	)	$	(559	)	$	(2,446	)

Weighted average number of shares used in the computation of basic earnings (loss) per share		1,131			1,119			1,110

Weighted average number of shares used in the computation of diluted earnings (loss) per share		1,131			1,119			1,110

Basic earnings (loss) per share are computed by dividing net income (loss) attributable to Teva’s ordinary shareholders by the weighted average number of ordinary shares outstanding (including fully vested RSUs and PSUs during the period), net of treasury shares.

In computing diluted loss per share for the years ended December 31, 2024, 2023 and 2022, no account was taken of the potential dilution that could occur upon the exercise of options and

non-vested

RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share.

Basic and diluted loss per share was $1.45 for the year ended December 31, 2024, compared to basic and diluted loss per share of $0.50 and $2.20 for the years ended December 31, 2023 and 2022, respectively.